Results 201 to 210 of about 62,107 (294)
Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait. [PDF]
Vadivelan AA, Coates T.
europepmc +1 more source
Persistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report
ABSTRACT Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue,
Riazullah +5 more
wiley +1 more source
Anemia of Chronic Disease: Pathophysiology, Diagnosis and Management. [PDF]
Abbotts K, Sriskandarajah P.
europepmc +1 more source
Concomitant burn injury and blast‐induced mild TBI lead to a magnified neuroimmune response shaped by endocrine stress‐related pathways and IL‐1R1‐dependent inflammatory signals, which also produce cytokine‐mediated impairment of erythropoiesis. These integrated systemic and CNS responses illustrate how inflammation, hematopoietic adaptation, and early
Hana C. Schwierling +7 more
wiley +1 more source
The pathological mechanisms and potential therapeutic strategies for renal anemia. [PDF]
Rao JX +5 more
europepmc +1 more source
Acute Neurological Events in Children With Hemoglobin SC Disease: A Multicenter Retrospective Study
ABSTRACT Introduction Neurological manifestations in children with hemoglobin SC (HbSC) disease remain insufficiently characterized, particularly regarding acute events. The aim of this study was to describe the spectrum and frequency of acute neurological events in a multicenter cohort of children with HbSC disease.
Célia Paulmin +11 more
wiley +1 more source
Obesity and Iron Metabolism: Mechanisms, Status Assessment, and Clinical Implications. [PDF]
Aguree S, Meng X.
europepmc +1 more source
ABSTRACT Purpose Anaemia is a common complication of chronic kidney disease, often treated with erythropoiesis‐stimulating agents (ESAs), but the optimal haemoglobin (Hb) target remains uncertain. Using electronic health records, we emulated a target trial comparing different Hb targets in haemodialysis patients to estimate their effects on mortality ...
Kate Birnie +6 more
wiley +1 more source

